Last reviewed · How we verify
IL-23 Therapy
IL-23 therapy inhibits the IL-23 signaling pathway to reduce pathogenic T-cell responses and inflammatory cytokine production.
IL-23 therapy inhibits the IL-23 signaling pathway to reduce pathogenic T-cell responses and inflammatory cytokine production. Used for Psoriasis, Inflammatory bowel disease (Crohn's disease and ulcerative colitis), Psoriatic arthritis.
At a glance
| Generic name | IL-23 Therapy |
|---|---|
| Also known as | Risankizumab, Ustekinumab, Guselkumab |
| Sponsor | Weill Medical College of Cornell University |
| Drug class | IL-23 inhibitor |
| Target | IL-23 (interleukin-23) |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
IL-23 is a key cytokine that drives Th17 cell differentiation and maintains inflammatory responses in autoimmune and inflammatory diseases. By blocking IL-23 or its receptor, this therapy reduces the expansion and activation of pro-inflammatory T cells, thereby suppressing disease-driving immune responses. This mechanism has shown efficacy in conditions characterized by IL-23-mediated inflammation, particularly in skin and gut-associated diseases.
Approved indications
- Psoriasis
- Inflammatory bowel disease (Crohn's disease and ulcerative colitis)
- Psoriatic arthritis
Common side effects
- Nasopharyngitis
- Upper respiratory tract infection
- Headache
- Injection site reactions
Key clinical trials
- Effect of Anti-Psoriatic Biologics on Risk of Anogenital Warts (CONDYPSO)
- Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis (PHASE4)
- Costa Rican Registry of IL-23 Inhibitors in Psoriatic Disease
- Guselkumab in the Treatment of Adults With Pyoderma Gangrenosum (PG) (PHASE2)
- A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis (PHASE2)
- Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD)
- LANDSCAPE: Demographics and Treatment Patterns of Patients With Immune-Mediated Inflammatory Skin Diseases in Italian Clinical Practice
- Ustekinumab for the Prevention of Acute Graft-versus-Host Disease After Unrelated Donor Hematopoietic Cell Transplant (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IL-23 Therapy CI brief — competitive landscape report
- IL-23 Therapy updates RSS · CI watch RSS
- Weill Medical College of Cornell University portfolio CI